drugset / Trial / NCT06233097

Esomeprazole Magnesium Dihydrate 40 mg Tablets Relative to Nexium 40 mg Tablets Under Fasting Condition

NCT06233097

Phase 1 Unknown 30 enrolled Bio-innova Co., Ltd
RandomizedCrossoverOpen-labelBasic science

Summary

The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be randomized, open-label, single dose, two way crossover design with two-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses

Timeline

Start
2024-08-29
Primary completion
2024-09-28
Completion
2024-10-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Oral

Indications

No indication recorded.